PDF(Pubmed)
Abstract：
Current literature primarily delves into the relationship between bronchiectasis and severe asthma, and only a few studies have evaluated the impact of bronchiectasis in patients with non-severe asthma. Therefore, this study investigated the clinical impact of bronchiectasis in patients with non-severe asthma. A prospective observational study of 140 non-severe asthmatic patients with (bronchiectasis group) and without bronchiectasis (control group) was conducted between September 2012 and February 2022. The bronchiectasis and control groups were compared in terms of demographics, lung function, asthma control test (ACT) results, exacerbation history, and respiratory medications. Among 140 non-severe asthmatic subjects, approximately 15.7% (n = 22) had bronchiectasis. The most common type of bronchiectasis was cylindrical type (90.7%). The left lingular division was the most frequently involved lung lobe (20.4%). There were no significant differences in the demographics (age, sex, body mass index, smoking history, and comorbidities) or ACT results between the 2 groups. The bronchiectasis group used inhaled corticosteroids/long-acting β2-agonists (P = 0.074) and mucolytics (P < 0.001) more frequently than the control group. Compared to the control group, the bronchiectasis group had lower forced expiratory volume in 1 second (FEV1) (L) (1.9 ± 0.7 L vs. 2.3 ± 0.9 L, P = 0.039) and FEV1%predicted (67.2 ± 22.2%predicted vs. 77.1 ± 20.0%predicted, P = 0.038). The rate of hospital admission to a general ward in the preceding year was significantly higher in the bronchiectasis group compared to those of the control group (23.8% vs. 3.5%, P = 0.005) with an adjusted odds ratio of 6.308 (95% confidence interval, 1.401-28.392). Patients with non-severe asthma and bronchiectasis had lower lung function and more frequent exacerbations requiring hospitalization than those without bronchiectasis. More attention is needed for asthmatic patients with bronchiectasis, even if the asthma is not severe.
摘要：
目前的文献主要探讨支气管扩张和严重哮喘之间的关系，只有少数研究评估了支气管扩张对非重度哮喘患者的影响.因此,本研究调查了支气管扩张对非重度哮喘患者的临床影响.在2012年9月至2022年2月之间，对140例非严重哮喘患者（支气管扩张组）和无支气管扩张（对照组）进行了前瞻性观察研究。在人口统计学方面比较支气管扩张组和对照组,肺功能,哮喘控制测试（ACT）结果，恶化史，和呼吸药物。在140名非重度哮喘患者中，约15.7%(n=22)患有支气管扩张.最常见的支气管扩张类型是圆柱型（90.7％）。左舌节是最常见的肺叶（20.4％）。人口统计学上没有显著差异(年龄，性别,身体质量指数,吸烟史,和合并症）或两组之间的ACT结果。支气管扩张组比对照组更频繁地使用吸入性糖皮质激素/长效β2-激动剂(P=0.074)和粘液溶解剂(P<0.001)。与对照组相比,支气管扩张组1秒用力呼气容积较低(FEV1)(L)(1.9±0.7Lvs.2.3±0.9L,P=0.039）和FEV1%预测（67.2±22.2%预测与预测77.1±20.0%，P=0.038)。与对照组相比，支气管扩张组上一年普通病房的住院率明显更高（23.8%vs.3.5%,P=0.005)，调整后的比值比为6.308(95%置信区间，1.401-28.392)。与没有支气管扩张的患者相比，非重度哮喘和支气管扩张的患者肺功能较低，需要住院治疗的加重频率更高。支气管扩张的哮喘患者需要更多的关注，即使哮喘并不严重。
